MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications

J Nucl Med. 2013 Dec;54(12):2182-8. doi: 10.2967/jnumed.113.122390. Epub 2013 Oct 15.

Abstract

The reliability of radiation dose estimates in internal radionuclide therapy is directly related to the accuracy of activity estimates obtained at each imaging time point. The recently published MIRD pamphlet no. 23 provided a general overview of quantitative SPECT imaging for dosimetry. The present document is the first in a series of isotope-specific guidelines that will follow MIRD 23 and focuses on one of the most commonly used therapeutic radionuclides, (131)I. The purpose of this document is to provide guidance on the development of protocols for quantitative (131)I SPECT in radionuclide therapy applications that require regional (normal organs, lesions) and 3-dimensional dosimetry.

Keywords: 131I; MIRD; SPECT/CT, dosimetry; quantitative SPECT.

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Calibration
  • Clinical Trials as Topic
  • Humans
  • Image Processing, Computer-Assisted
  • Iodine Radioisotopes
  • Radioimmunotherapy
  • Radiometry
  • Recombinant Fusion Proteins / pharmacokinetics
  • Recombinant Fusion Proteins / therapeutic use
  • Time Factors
  • Tomography, Emission-Computed, Single-Photon / methods*
  • Tomography, X-Ray Computed

Substances

  • Antibodies
  • Antibodies, Monoclonal
  • Iodine Radioisotopes
  • Recombinant Fusion Proteins
  • SIP(L19) fusion protein
  • tositumomab I-131